Metastasis (plural: metastases) is the spread of malignant cells from a primary tumor to a distant anatomical site, where they establish independent secondary tumors through a multi-step cascade: local invasion of surrounding tissue → intravasation into blood or lymphatic vessels → survival in circulation → extravasation into a target organ → colonization and proliferation at the secondary site. It is the defining feature that distinguishes malignant neoplasms from benign ones and is the leading cause of cancer-related mortality. Common metastatic destinations are broadly summarized by the seed and soil hypothesis: breast cancer seeds preferentially to bone, liver, lung, and brain; prostate cancer to bone; colorectal cancer to liver and peritoneum; and lung cancer to the brain, adrenals, and bone. For AAPC-certified inpatient profee coders, metastasis coding is one of the highest-complexity and highest-impact areas in all of ICD-10-CM. The sequencing rules are specific: when the patient is admitted for treatment of a secondary (metastatic) site, the secondary neoplasm code (C77-C79) is sequenced as principal diagnosis and the primary site code (C00-C75) is added as an additional diagnosis — even if the primary tumor is still present. When the primary is unknown, use C80.1 (malignant neoplasm without specification of site) for the primary. Each secondary site requires its own billable code, and missing individual metastatic site codes is a consistent source of DRG undercoding and risk-adjustment loss in inpatient oncology.
Greek μετά (metá) — “after, beyond, among; change of place or condition”
One of the most productive prefixes in medical terminology; in this context conveys change of position or transfer; also appears in metabolism (change of substance), metaphysis (beyond the growth plate), metaplasia (change of form)
Greek στάσις (stásis) — “a standing, a position, a state of being placed”; from histanai — “to cause to stand, to place”; PIE root *stā- — “to stand, make or be firm”
Appears across medicine as hemostasis (blood standing still), homeostasis (same standing), bacteriostasis (bacterial growth arrested); in metastasis the combination literally yields “a change of standing” or “a removal to another place”
The word metastasis is first attested in the 6th-5th century BCE in Greek — the lyric poet Simonides used it to mean a “removal” or “change of place.” In Hippocratic and later medical Greek, metastasis was applied broadly to describe the transfer of disease or symptoms from one body part to another — still much broader than its modern oncologic meaning. It entered Latin as a rhetorical term meaning “rapid transition in subjects” and appeared in English medical literature by the late 16th century (first recorded 1580-90) in the broader sense of a shift or transference of disease. The specifically oncological meaning — spread of cancer cells to distant sites — did not narrow and solidify until the mid-19th century with the work of Rudolf Virchow and the development of cellular pathology. The adjective form metastatic and the verb to metastasize followed in the same period. The plural metastases (Greek plural of -asis → -ases) is used universally in clinical documentation and should be recognized in operative reports, pathology notes, and imaging reads — all of which drive code assignment.
🔀 ALIASES / ALTERNATE TERMS
Term
Relationship
Mets
Clinical shorthand; acceptable in documentation; recognized by coders
Metastatic disease
Broad descriptor; implies Stage IV in most solid tumor staging systems
Secondary malignancy / Secondary neoplasm
ICD-10-CM preferred language — C77, C78, C79 family descriptors use “secondary”
Distant metastasis
TNM staging term (M1); implies spread beyond regional lymph nodes
Regional metastasis
Spread to regional lymph nodes — coded C77 family
Occult metastasis
Clinically undetected; found incidentally on pathology; still coded when confirmed
Carcinomatosis
Widespread peritoneal metastasis; coded C78.6 (secondary malignant neoplasm of retroperitoneum and peritoneum)
Coded C78.7; most common abdominal metastatic site
Malignant neoplasm, unknown primary
When primary site cannot be determined; coded C80.1
🔗 RELATED TERMS
Primary malignant neoplasm — the original tumor site from which metastasis arose; coded C00-C75; always coded additionally when known, regardless of whether it is still present
TNM staging — Tumor-Node-Metastasis; M0 = no distant metastasis; M1 = distant metastasis present; M1 = Stage IV in most solid tumor classifications; drives treatment planning and coding context
Carcinoma in situ — localized malignancy with no invasion or metastatic potential; coded D00-D09; the biological opposite of metastasis
Surgical pathology — definitive confirmation of metastasis; CPT 88305 (Level IV — excisional biopsy specimen) or 88307 (Level V — complex resection); always pair with surgical CPT
Stereotactic radiosurgery (SRS) — targeted radiation for brain and other metastases; e.g., Gamma Knife, CyberKnife; CPT 61796 (single brain lesion) / 61797 (add-on, each additional)
Radiofrequency ablation (RFA) — percutaneous thermal destruction of metastatic tumors; CPT varies by organ site — liver (47382), lung (32998), bone (20982)
Palliative care — mainstay of management for widely metastatic disease; Z51.5 (encounter for palliative care) coded additionally when palliative intent is documented
Malignant pleural effusion — common complication of metastatic lung, breast, and lymphoma; coded J91.0; drives thoracentesis and pleurodesis procedures
Pathological fracture — fracture through bone weakened by metastatic disease; coded M84.5- family with 7th character for encounter type; an extremely common inpatient scenario
Spinal cord compression — metastatic epidural disease compressing the cord; coded G99.2 when due to neoplasm; neurological emergency; drives surgical and radiation CPT
PET scan — positron emission tomography; primary whole-body staging and restaging tool for metastasis detection; CPT 78816 (whole body with CT) / 78814 (limited)
⚠️ SEQUENCING RULES: When admitted for treatment of a SECONDARY (metastatic) site, the SECONDARY code (C77-C79) is PRINCIPAL. The primary tumor code is ADDITIONAL. When admitted to treat the PRIMARY tumor and metastasis is incidental, the primary tumor is PRINCIPAL. When primary site is unknown, use C80.1 for the primary. C77, C78, and C79 parent codes are NOT billable — child codes are required. Each metastatic site requires its own separate code.
Secondary Malignant Neoplasm of Lymph Nodes — C77 Family
Encounter for palliative care (add when palliative intent explicitly documented — affects DRG and quality metrics)
Z85.-
Personal history of malignant neoplasm (when primary has been excised/eradicated; historical only; do NOT use as current diagnosis with active C77-C79)
⚠️ CPT 2025 deleted codes 49203-49205 (intra-abdominal tumor excision by largest tumor size) and replaced them with new codes 49186-49190 based on TOTAL sum of maximum length of all tumors removed. Do NOT use deleted codes 49203-49205 on any 2025 or later claims — they will deny. Verify the correct ablation CPT by organ site — each organ has its own site-specific ablation code family.
Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura, including imaging guidance when performed, unilateral; radiofrequency (lung metastasis RFA)
Ablation, bone tumor(s) (e.g., osteoid osteoma, metastasis), radiofrequency, percutaneous, including imaging guidance (bone metastasis RFA — also for pain palliation in osteolytic mets)
Excision or destruction of intra-abdominal primary or secondary tumor(s) or cyst(s), open; total sum ≤5 cm (REPLACES deleted 49203 — use for peritoneal/abdominal mets)
Distinct procedural service — e.g., biopsy of liver met (47000) distinct from biopsy of lung met (32408) same session; PET (78816) distinct from therapeutic procedure same day
Professional component — PET scan and imaging interpretation when physician reads without owning equipment; also for 88305/88307 pathology interpretation
Staged procedure — planned second-stage resection or ablation within global period of first procedure
⚠️ Coding Notes & Payer Guidance
Sequencing is the #1 coding challenge in metastasis: ICD-10-CM Official Guidelines Section I.C.2 governs neoplasm sequencing. The principal rule: sequence the site being treated. If the patient is admitted to treat the liver metastasis, C78.7 is principal and the primary tumor code is additional. If admitted to treat the primary breast cancer and liver mets are incidentally managed, the primary breast code leads. When the admission is for a complication of metastatic disease (e.g., malignant pleural effusion J91.0, pathological fracture M84.551A, or spinal cord compression G99.2), the complication code may be principal if it is the reason for admission — followed by the metastatic site code and primary tumor code. Getting this wrong misassigns the DRG and misrepresents the clinical picture.
CPT 2025: Deleted 49203-49205 — do NOT use: These three intra-abdominal tumor excision codes were deleted effective January 1, 2025. The replacement codes 49186, 49187, and 49188 use total sum of maximum tumor lengths rather than the single largest tumor size. This is a fundamental change in how cytoreductive surgery for peritoneal metastasis (carcinomatosis) is measured and coded — verify with your surgeons that operative reports document total tumor burden measurement.
Unknown primary — use C80.1, not C80.0:C80.1 (malignant neoplasm without specification of site) is the correct code for cancers of unknown primary (CUP). C80.0 (disseminated malignant neoplasm, unspecified) is reserved for widely metastatic disease where the treatment is directed at the systemic disease without a specific secondary site. These are clinically and reimbursement-distinctly different — do not interchange them.
Each metastatic site = its own code: ICD-10-CM requires a separate code for each documented metastatic site. Bone AND liver AND lung metastases = C79.51 + C78.7 + C78.00 (or site-specific lung code). Coding only one metastatic site when multiple are documented is undercoding — each site may carry risk-adjustment and DRG weight.
Z51.5 — palliative care is a missed code: When a provider documents palliative intent or palliative care in the context of metastatic disease, Z51.5 should be added as an additional diagnosis. It is consistently omitted and affects quality reporting, case mix documentation, and certain value-based care metrics. It does NOT change the principal diagnosis but belongs on the claim.
SRS add-on codes 61797 and 61799 are frequently missed: When stereotactic radiosurgery treats multiple brain metastases in a single session, 61796 covers the first simple lesion and 61797 must be reported for each additional simple lesion. Missing the add-on units is one of the most common undercoding patterns in neurosurgery and radiation oncology profee billing.
Crystal's MCW Coder Hub